Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, and myasthenia gravis are now recruiting.
Latest Quarterly or Annual Filing
Latest Current Report
Latest Proxy Statement
View All SEC Filings
View and filter by group or type
View All Filings